Simple faecal preparation and efficacy of frozen inoculum in faecal microbiota transplantation for recurrent Clostridium difficile infection - An observational cohort study

Alimentary Pharmacology and Therapeutics

Volumn 41, Issue 1, 2015, Pages 46-53

  Satokari, R ^a   Mattila, E ^b   Kainulainen, V ^a   Arkkila, P E T ^b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BIOLOGICAL THERAPY; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; COLONOSCOPY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; FECAL MICROBIOTA TRANSPLANTATION; FECES MICROFLORA; FEMALE; FEVER; FOLLOW UP; FREEZING; HUMAN; MALE; OBSERVATIONAL STUDY; PATIENT SAFETY; RECURRENT INFECTION; STORAGE TEMPERATURE; THERAPY EFFECT; TREATMENT OUTCOME; CLOSTRIDIUM INFECTIONS; COLON; DONOR; FECES; MICROBIOLOGY; MICROFLORA; MIDDLE AGED; PROCEDURES; RETROSPECTIVE STUDY; TISSUE TRANSPLANTATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CLOSTRIDIUM INFECTIONS; COLON; COLONOSCOPY; FECES; FEMALE; HUMANS; MALE; MICROBIOTA; MIDDLE AGED; RETROSPECTIVE STUDIES; TISSUE DONORS; TISSUE TRANSPLANTATION; TREATMENT OUTCOME;

EID: 84915804068     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13009     Document Type: Article

References (42)

1. Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 2009; 7: 526-36.
2. Borody TJ, Khoruts A. Fecal microbiota transplantation and emerging applications. Nat Rev Gastroenterol Hepatol 2011; 9: 88-96.
3. Brace C, Gloor GB, Ropeleski M, Allen-Vercoe E, Petrof E. Microbial composition analysis of Clostridium difficile infections in an ulcerative colitis patient treated with multiple fecal microbiota transplantations. J Crohns Colitis 2014; 8: 1133-7.
4. Honda H, Dubberke ER. The changing epidemiology of Clostridium difficile infection. Curr Opin Gastroenterol 2014; 30 : 54-62.
5. Redelings MD, Sorvillo F, Mascola L. Increase in Clostridium difficile-related mortality rates, United States, 1999-2004. Emerg Infect Dis 2007; 13: 1417-9.
6. Tan XQ, Verrall AJ, Jureen R, et al. The emergence of community-onset Clostridium difficile infection in a tertiary hospital in Singapore: a cause for concern. Int J Antimicrob Agents 2014; 43: 47-51.
7. Wendt JM, Cohen JA, Mu Y, et al. Clostridium difficile infection among children across diverse US geographic locations. Pediatrics 2014; 133: 651-8.
8. Burckhardt F, Friedrich A, Beier D, Eckmanns T. Clostridium difficile surveillance trends, Saxony, Germany. Emerg Infect Dis 2008; 14: 691-2.
9. Gravel D, Miller M, Simor A, et al. Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program Study. Clin Infect Dis 2009; 48: 568-76.
10. Crook DW, Walker AS, Kean Y, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection: metaanalysis of pivotal randomized controlled trials. Clin Infect Dis 2012; 55: S93-103.
11. Garey KW, Ghantoji SS, Shah DN, et al. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium dif ficile infection. J Antimicrob Chemother 2011; 66: 2850-5.
12. Johnson S, Schriever C, Patel U, Patel T, Hecht DW, Gerding DN. Rifaximin Redux: treatment of recurrent Clostridium dif ficile infections with rifaximin immediately post-vancomycin treatment. Anaerobe 2009; 15: 290-1.
13. Mattila E, Uusitalo-Seppala R, Wuorela M, et al. Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection. Gastroenterology 2012; 142: 490-6.
14. Mattila E, Arkkila P, Mattila PS, Tarkka E, Tissari P, Anttila VJ. Rifaximin in the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther 2013; 37: 122-8.
15. Musher DM, Logan N, Bressler AM, Johnson DP, Rossignol JF. Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. Clin Infect Dis 2009; 48: e41-6.
16. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile . N Engl J Med 2013; 368: 407-15.
17. Juang P, Skledar SJ, Zgheib NK, et al. Clinical outcomes of intravenous immunoglobulin in severe Clostridium dif ficile-associated diarrhoea. Am J Infect Control 2007; 35: 131-7.
18. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364: 422-31.
19. Sougioultzis S, Kyne L, Drudy D, et al. Clostridium dif ficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 2005; 128: 764-70.
20. Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for Clostridium dif ficile infection: systematic review and meta-analysis. Am J Gastroenterol 2013; 108: 500-8.
21. Brandt LJ, Aroniadis OC, Mellow M, et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol 2012; 107: 1079-87.
22. Brandt LJ, Reddy SS. Fecal microbiota transplantation for recurrent Clostridium dif ficile infection. J Clin Gastroenterol 2011; 45: S159-67.
23. Lee CH, Belanger JE, Kassam Z, et al. The outcome and long-term follow-up of 94 patients with recurrent and refractory Clostridium difficile infection using single to multiple fecal microbiota transplantation via retention enema. Eur J Clin Microbiol Infect Dis 2014; 33: 1425-8.
24. Hamilton MJ, Weingarden AR, Sadowsky MJ, Khoruts A. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium dif ficile infection. Am J Gastroenterol 2012; 107: 761-7.
25. Gutman J, Kurchin A. Split donation fecal microbiota transplantation. Am J Gastroenterol 2013; 108: 1659-60.
26. Lo Vecchio A, Cohen MB. Fecal microbiota transplantation for Clostridium dif ficile infection: benefits and barriers. Curr Opin Gastroenterol 2014; 30: 47-53.
27. Youngster I, Sauk J, Pindar C, et al. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin Infect Dis 2014; 58: 1515-22.
28. Emanuelsson F, Claesson BE, Ljungstrom L, Tvede M, Ung KA. Faecal microbiota transplantation and bacteriotherapy for recurrent Clostridium dif ficile infection: a retrospective evaluation of 31 patients. Scand J Infect Dis 2014; 46: 89-97.
29. Goorhuis A, Van der Kooi T, Vaessen N, et al. Spread and epidemiology of Clostridium dif ficile polymerase chain reaction ribotype 027/toxinotype III in The Netherlands. Clin Infect Dis 2007; 45: 695-703.
30. Kuijper EJ, Barbut F, Brazier JS, et al. Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008. Euro Surveill 2008; 13: 18942.
31. Fuentes S, van Nood E, Tims S, et al. Reset of a critically disturbed microbial ecosystem: faecal transplant in recurrent Clostridium difficile infection. ISME J 2014; 8: 1621-33.
32. Duncan SH, Louis P, Flint HJ. Cultivable bacterial diversity from the human colon. Lett Appl Microbiol 2007; 44: 343-50.
33. Rajilić-Stojanović M, de Vos WM. The first 1000 cultured species of the human gastrointestinal microbiota. FEMS Microbiol Rev 2014; 38: 996-1047.
34. Rigottier-Gois L. Dysbiosis in inflammatory bowel diseases: the oxygen hypothesis. ISME J 2013; 7: 1256-61.
35. Angelberger S, Reinisch W, Makristathis A, et al. Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am J Gastroenterol 2013; 108: 1620-30.
36. Kump PK, Gröchenig HP, Lackner S, et al. Alteration of intestinal dysbiosis by fecal micro-biota transplantation does not induce remission in patients with chronic active ulcerative colitis. Inflamm Bowel Dis 2013; 19: 2155-65.
37. Kassam Z, Lee CH, Yuan Y, Hunt RH. Navigating long-term safety in fecal microbiota transplantation. Am J Gastroenterol 2013; 108: 1538.
38. Reynolds JEF. Martindale: The Extra Pharmacopoeia. 31st ed. London: Royal Pharmaceutical Society, 1996.
39. European Food Safety Organization (EFSA), Scientific Committee of Foods. Opinion on Certain Additives for Use in Foods for Infants and Young Children in Good Health and in Foods for Special Medical Purposes for Infants and Young Children (expressed on 21 March 1997 and amended on 13 June 1997), 1997. Available at: http://ec.europa.eu/food/fs/sc/oldcomm7/out06-en.html (accessed 26 April 2014).
40. Smits LP, Bouter KE, de Vos WM, Borody TJ, Nieuwdorp M. Therapeutic potential of fecal microbiota transplantation. Gastroenterology 2013; 145: 946-53.
41. Sha S, Liang J, Chen M, et al. Systematic review: faecal microbiota transplantation therapy for digestive and nondigestive disorders in adults and children. Aliment Pharmacol Ther 2014; 39: 1003-32.
42. Petrof EO, Khoruts A. From stool transplants to next-generation microbiota therapeutics. Gastroenterology 2014; 146: 1573-82.